Fig. 7.

The detrimental effect of IgG3 CH1-hinge on anti-DR5 antibody agonism. a–c Quantification of the percentage of Annexin V⁺PI⁻ (a, b) or active caspase-3-positive (c) apoptotic cells among MC38 cells co-cultured with FcγR-humanized (a–c), Fcgrα^−/− (b), or without (c) mouse splenocytes for 4 h in the presence of indicated control IgG or anti-DR5 mAbs (a–c) with/without human FcγRIIB-blocking antibody 2B6 (b). d Quantification of AST levels in FcγR-humanized mice treated with indicated control or anti-DR5 antibodies 6 days earlier (crosses symbolize mortality). e Survival curve of mice in (d). Numbers of mice: d, e four mice per group except for seven mice in the αDR5:V11(H1) group. Bars represent the mean ± SEM. ^*p ≤ 0.05, ^**p ≤ 0.01, ^***p ≤ 0.001, ^****p ≤ 0.0001, one-way ANOVA Sidak’s multiple comparisons test (a), two-way ANOVA Sidak’s multiple comparisons test (b, c), and Gehan–Breslow–Wilcoxon test (d). Source data are provided as a Source Data file. A representative of three (a–c), or two (d, e) independent experiments is shown